AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34146476 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 5-15 years
Number of subjects: 531
Study 34146476 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals younger than 5 years
Number of subjects: 531
Study 34146476 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals 16 years or older
Number of subjects: 531
Study 34146476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosquito feeding experiments
Number of subjects: 531
Study 34146476 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples from four children
Number of subjects: 531
Study 32150057 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer worker discharge intervention plus usual care
Number of subjects: 590
Study 32150057 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 590
Study 36030343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 106
Study 32085529 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 400 U
Number of subjects: 0
Study 32085529 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 240 U
Number of subjects: 0
Study 32085529 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 400 U (open-label phase)
Number of subjects: 0
Study 35022754 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK)
Number of subjects: 0
Study 33736944 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (Neuromuscular Electrical Stimulation) applied at time of surgery
Number of subjects: 40
Study 33736944 — intervention group
Group type: COMPARATOR
Intervention: Sham device (subtherapeutic electrical stimulation)
Number of subjects: 40
Study 33736944 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 40
Study 33736944 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 40
Study 35121493 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL16 plasma levels in COVID-19 hospitalized patients
Number of subjects: 115
Study 34450552 — intervention group
Group type: EXPERIMENTAL
Intervention: idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC)
Number of subjects: 2887
Study 34450552 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by tailored and dose-dense docetaxel (dtD) (dtEC-dtD)
Number of subjects: 2887
Study 34450552 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 2887
Study 32357913 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS pathway management
Number of subjects: 400
Study 32357913 — intervention group
Group type: COMPARATOR
Intervention: Traditional management mode
Number of subjects: 400
Study 36050801 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application PromMera
Number of subjects: 140
Study 36050801 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 140
Study 33899526 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor Platelet-Rich Plasma (LP-PRP) plus Hyaluronic Acid (HA)
Number of subjects: 50
Study 33899526 — intervention group
Group type: COMPARATOR
Intervention: Autologous Microfragmented Adipose Tissue (AMAT)
Number of subjects: 50
Study 34895483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrecizumab (8 mg/kg bodyweight)
Number of subjects: 150
Study 34895483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 34895483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Number of subjects: 150
Study 32740502 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 µg/kg IND
Number of subjects: 61
Study 32740502 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 µg/kg IND
Number of subjects: 61
Study 36441845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0
Study 36441845 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS
Number of subjects: 0
Study 36441845 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 33361553 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT group (n=42)
Number of subjects: 87
Study 33361553 — intervention group
Group type: COMPARATOR
Intervention: PV group (n=45)
Number of subjects: 87
Study 32096064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 32096064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study 32096064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewed or integer prasugrel
Number of subjects: 0
Study 32096064 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study 33243799 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision support system (CDSS) intervention
Number of subjects: 18
Study 33243799 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 18
Study 33742520 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K (menadiol diphosphate 5 mg, thrice weekly)
Number of subjects: 90
Study 33742520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32421762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin mass drug administration (MDA) for scabies
Number of subjects: 0
Study 33859155 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-Tacrolimus (LCPT)
Number of subjects: 55
Study 33859155 — intervention group
Group type: COMPARATOR
Intervention: Immediate-Release Tacrolimus (IR-Tac)
Number of subjects: 55
Study 35272418 — intervention group
Group type: EXPERIMENTAL
Intervention: Auxiliary acupuncture device
Number of subjects: 0
Study 35272418 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture device
Number of subjects: 0
Study 32615658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy (once a week for three weeks)
Number of subjects: 92
Study 32615658 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) (two times with seven days interval)
Number of subjects: 92
Study 32615658 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS) (2ml injected two times every seven days)
Number of subjects: 92
Study 35028992 — intervention group
Group type: EXPERIMENTAL
Intervention: DiabetesFlex (patient-controlled flexible visits using patient-reported, outcome-based telehealth follow-up)
Number of subjects: 343
Study 35028992 — intervention group
Group type: EXPERIMENTAL
Intervention: DiabetesFlex
Number of subjects: 343
Study 35028992 — intervention group
Group type: COMPARATOR
Intervention: Standard care (face-to-face visits every 4 months)
Number of subjects: 343
Study 32000711 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg, thrice a day)
Number of subjects: 43
Study 32000711 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg, once a day)
Number of subjects: 43
Study 35210069 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized yoga training program in addition to current guideline‐based therapy
Number of subjects: 55
Study 35210069 — intervention group
Group type: COMPARATOR
Intervention: Current guideline‐based therapy alone
Number of subjects: 55
Study 32781104 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (pembro) alone
Number of subjects: 20
Study 32781104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with radiation therapy (pembroRT)
Number of subjects: 20
Study 32781104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pembro and pembroRT)
Number of subjects: 20
Study 32781104 — intervention group
Group type: EXPERIMENTAL
Intervention: pembroRT
Number of subjects: 20
Study 32819979 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 novel circulating biomarkers added to standard predictors
Number of subjects: 1998
Study 32819979 — intervention group
Group type: COMPARATOR
Intervention: Standard predictors only
Number of subjects: 1998
Study 32819979 — intervention group
Group type: EXPERIMENTAL
Intervention: Log(calprotectin) and log(cathepsin-S)
Number of subjects: 1998
Study 35505658 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction diet with a low glycemic index (D group)
Number of subjects: 40
Study 35505658 — intervention group
Group type: COMPARATOR
Intervention: Weight-reduction diet with a low glycemic index and Lactobacillus rhamnosus supplementation (DP group)
Number of subjects: 40
Study 33228950 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise program under physiotherapist supervision followed by independent home-based program
Number of subjects: 150
Study 33228950 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 150
Study 34171789 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF 320/18/9.6 μg
Number of subjects: 8509
Study 34171789 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF 160/18/9.6 μg
Number of subjects: 8509
Study 34171789 — intervention group
Group type: COMPARATOR
Intervention: GFF 18/9.6 μg
Number of subjects: 8509
Study 34171789 — intervention group
Group type: COMPARATOR
Intervention: BFF 320/9.6 μg
Number of subjects: 8509
Study 33115408 — intervention group
Group type: EXPERIMENTAL
Intervention: IV propofol
Number of subjects: 80
Study 33115408 — intervention group
Group type: COMPARATOR
Intervention: IH sevoflurane
Number of subjects: 80
Study 33985595 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-donor FMT (capsules containing the fecal microbiota of four sex-matched lean donors)
Number of subjects: 87
Study 33985595 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline capsules)
Number of subjects: 87
Study 33985595 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-donor FMT
Number of subjects: 87
Study 35912158 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory training
Number of subjects: 58
Study 35912158 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative pain nursing (Control)
Number of subjects: 58
Study 33507721 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG plus GnRH agonist (group B)
Number of subjects: 114
Study 33507721 — intervention group
Group type: COMPARATOR
Intervention: hCG only (group A)
Number of subjects: 114
Study 32243644 — intervention group
Group type: EXPERIMENTAL
Intervention: SED-ACT (sedentary time interrupted with 2 minutes of moderate-intensity arm crank ergometer physical activity every 20 minutes)
Number of subjects: 14
Study 32243644 — intervention group
Group type: COMPARATOR
Intervention: SED (uninterrupted sedentary time)
Number of subjects: 14
Study 32851885 — intervention group
Group type: EXPERIMENTAL
Intervention: OS nomogram incorporating age, race, histologic grade, AJCC stage, metastasis, surgery, chemotherapy, and tumor size.
Number of subjects: 1149
Study 32851885 — intervention group
Group type: EXPERIMENTAL
Intervention: CSS nomogram
Number of subjects: 1149
Study 34030331 — intervention group
Group type: EXPERIMENTAL
Intervention: Forage allowance of 12% LW
Number of subjects: 0
Study 34030331 — intervention group
Group type: EXPERIMENTAL
Intervention: Forage allowance of 16% LW
Number of subjects: 0
Study 34030331 — intervention group
Group type: EXPERIMENTAL
Intervention: Forage allowance of 8% LW
Number of subjects: 0
Study 34030331 — intervention group
Group type: EXPERIMENTAL
Intervention: Forage allowance of 4% LW
Number of subjects: 0
Study 34030331 — intervention group
Group type: EXPERIMENTAL
Intervention: Forage allowance of 8–12% LW
Number of subjects: 0
Study 34030331 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing forage allowance
Number of subjects: 0
Study 32858860 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-strain probiotics
Number of subjects: 39
Study 32858860 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-strain probiotics
Number of subjects: 39
Study 32858860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 39
Study 33214244 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg emixustat
Number of subjects: 23
Study 33214244 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg emixustat
Number of subjects: 23
Study 33214244 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg emixustat
Number of subjects: 23
Study 32480307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (PRM) 2 mg for 4 weeks
Number of subjects: 34
Study 32480307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 35191169 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label trials
Number of subjects: 86
Study 35191169 — intervention group
Group type: COMPARATOR
Intervention: Open-label arm
Number of subjects: 86
Study 35191169 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label design
Number of subjects: 86
Study 33677400 — intervention group
Group type: COMPARATOR
Intervention: 12L:12D
Number of subjects: 300
Study 33677400 — intervention group
Group type: EXPERIMENTAL
Intervention: 14L:10D
Number of subjects: 300
Study 33677400 — intervention group
Group type: EXPERIMENTAL
Intervention: 16L:8D
Number of subjects: 300
Study 33677400 — intervention group
Group type: EXPERIMENTAL
Intervention: 18L:6D
Number of subjects: 300
Study 33677400 — intervention group
Group type: EXPERIMENTAL
Intervention: 20L:4D
Number of subjects: 300
Study 33677400 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥16 h photoperiods
Number of subjects: 300
Study 33677400 — intervention group
Group type: EXPERIMENTAL
Intervention: 16L:8D and 18L:6D
Number of subjects: 300
Study 33677400 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-hour photoperiod
Number of subjects: 300
Study 32926814 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin-based triple therapy (RHB-105)
Number of subjects: 0
Study 32926814 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin + omeprazole
Number of subjects: 0
Study 34020852 — intervention group
Group type: EXPERIMENTAL
Intervention: Shod walking
Number of subjects: 74
Study 34020852 — intervention group
Group type: COMPARATOR
Intervention: Barefoot walking
Number of subjects: 74
Study 34020852 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor walking
Number of subjects: 74
Study 34020852 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 74
Study 34020852 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups
Number of subjects: 74
Study 34059916 — intervention group
Group type: COMPARATOR
Intervention: Control (9 hours sleep opportunities)
Number of subjects: 36
Study 34059916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (5 hours sleep opportunities)
Number of subjects: 36
Study 34059916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction with weekend recovery sleep (5 days insufficient sleep, 2 days ad libitum weekend recovery sleep)
Number of subjects: 36
Study 34059916 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 32618626 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Oxygen (HFNO) during apnea
Number of subjects: 20
Study 32618626 — intervention group
Group type: COMPARATOR
Intervention: High-Flow Nasal Oxygen (HFNO) during spontaneous ventilation (SV)
Number of subjects: 20
Study 32459377 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G7 intervention
Number of subjects: 461
Study 32459377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 461
Study 35766022 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily
Number of subjects: 60
Study 35766022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33811477 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 62
Study 32277954 — intervention group
Group type: EXPERIMENTAL
Intervention: Maggot excretions/secretions (ES)
Number of subjects: 0
Study 32277954 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of miR-18a/19a or overexpression of TSP-1
Number of subjects: 0
Study 35156999 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-Loop Spinal Cord Stimulation
Number of subjects: 0
Study 35156999 — intervention group
Group type: COMPARATOR
Intervention: Open-Loop Spinal Cord Stimulation
Number of subjects: 0
Study 33104449 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletive DMTs
Number of subjects: 45
Study 33104449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequestrating DMTs
Number of subjects: 45
Study 36244398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemarituzumab (15 mg/kg bodyweight) plus mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 hours)
Number of subjects: 155
Study 36244398 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 bolus followed by 2400 mg/m2 over 46 hours)
Number of subjects: 155
Study 36244398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Number of subjects: 155
Study 36244398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 32431238 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward social comparison
Number of subjects: 1679
Study 32431238 — intervention group
Group type: EXPERIMENTAL
Intervention: Basking-in-Reflected-Glory (BIRG)
Number of subjects: 1679
Study 32431238 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no self-enhancement)
Number of subjects: 1679
Study 34922231 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing rescuers every 1 minute during CPR
Number of subjects: 56
Study 34922231 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR with rescuer change every 2 minutes
Number of subjects: 56
Study 35958677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dry needling (group D)
Number of subjects: 54
Study 35958677 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapeutic treatment (group P)
Number of subjects: 54
Study 32805363 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia
Number of subjects: 0
Study 32805363 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (Control)
Number of subjects: 0
Study 34724336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 8568
Study 35636380 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (80 mg/day)
Number of subjects: 60
Study 35636380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32578279 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (SC-t) 600mg every 3 weeks for 4 cycles
Number of subjects: 166
Study 32578279 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab (IV-t)
Number of subjects: 166
Study 32578279 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab with single injection device (SID)
Number of subjects: 166
Study 32578279 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professional preference for SC-t
Number of subjects: 166
Study 32578279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to SC-t
Number of subjects: 166
Study 35881908 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB continued throughout the study period
Number of subjects: 0
Study 35881908 — intervention group
Group type: COMPARATOR
Intervention: Without ACEI/ARB (stopped 24 hours before and continued 48 hours after the procedure)
Number of subjects: 0
Study 35881908 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB continued in patients with eGFR < 45 mL/min
Number of subjects: 0
Study 35881908 — intervention group
Group type: COMPARATOR
Intervention: Without ACEI/ARB in patients with eGFR < 45 mL/min
Number of subjects: 0
Study 35881908 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB continued in patients with eGFR ≥ 45 mL/min
Number of subjects: 0
Study 35881908 — intervention group
Group type: COMPARATOR
Intervention: Without ACEI/ARB in patients with eGFR ≥ 45 mL/min
Number of subjects: 0
Study 33639918 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor knowledge about epilepsy
Number of subjects: 732
Study 33639918 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable attitude towards epilepsy
Number of subjects: 732
Study 33639918 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with poor knowledge
Number of subjects: 732
Study 33639918 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with unfavorable attitude
Number of subjects: 732
Study 32463090 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in randomized trials
Number of subjects: 232
Study 33103272 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlated scrambling variables in randomized response technique
Number of subjects: 0
Study 33103272 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed estimator of mean
Number of subjects: 0
Study 33103272 — intervention group
Group type: EXPERIMENTAL
Intervention: Variance estimator of the proposed estimator of mean
Number of subjects: 0
Study 33103272 — intervention group
Group type: EXPERIMENTAL
Intervention: Real primary data on smoking
Number of subjects: 0
Study 32452561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-transjugular intrahepatic porto-systemic shunt (TIPSS)
Number of subjects: 58
Study 32452561 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 58
Study 32452561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-transjugular intrahepatic porto-systemic shunt (TIPSS) per-protocol
Number of subjects: 58
Study 35776283 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band exercise
Number of subjects: 60
Study 35105604 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured prehabilitation exercise intervention during neoadjuvant chemotherapy
Number of subjects: 40
Study 35458201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous Ammonium Phosphate (FAP)
Number of subjects: 39
Study 35458201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate (FeSO4)
Number of subjects: 39
Study 35458201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Pyrophosphate (FePP)
Number of subjects: 39
Study 33587541 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-World Evidence (RWE) from hybrid study designs incorporating aspects of randomized clinical trials
Number of subjects: 0
Study 33587541 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioventus Observational Non-Interventional EXOGEN Studies (BONES)
Number of subjects: 0